🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise globally, with figures suggesting over 82 million infections each year. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization marks a major breakthrough in the therapy of superbug gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Data and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug cured more than 90% of cases of the STI. This establishes an comparable level with the current standard treatment, which combines two antibiotics. The research included hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Doctors treating patients have voiced optimism. Having a one-pill regimen of this kind is described as a "critical tool" for managing the epidemic. This is viewed as crucial to alleviate the strain of the illness for patients and to halt the transmission of extremely resistant gonorrhoea around the world.